{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:17:41Z","timestamp":1780391861233,"version":"3.54.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.hfc.2010.02.001","type":"journal-article","created":{"date-parts":[[2010,6,21]],"date-time":"2010-06-21T04:21:13Z","timestamp":1277094073000},"page":"347-357","source":"Crossref","is-referenced-by-count":16,"title":["Anemia in Chronic Kidney Disease: New Advances"],"prefix":"10.1016","volume":"6","author":[{"given":"Tejas V.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hfc.2010.02.001_bib1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0272-6386(96)90130-4","article-title":"The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease","volume":"28","author":"Foley","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.hfc.2010.02.001_bib2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1681\/ASN.2006101097","article-title":"Iron regulation","volume":"18","author":"Himmelfarb","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.hfc.2010.02.001_bib3","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJM199912233412607","article-title":"Disorders of iron metabolism","volume":"341","author":"Andrews","year":"1999","journal-title":"N Engl J\u00a0Med"},{"key":"10.1016\/j.hfc.2010.02.001_bib4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1681\/ASN.2006080908","article-title":"Renal iron metabolism: transferrin iron delivery and the role of iron regulatory proteins","volume":"18","author":"Zhang","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.hfc.2010.02.001_bib5","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2003-03-0672","article-title":"Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation","volume":"102","author":"Ganz","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hfc.2010.02.001_bib6","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/blood-2002-04-1260","article-title":"Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease","volume":"100","author":"Weinstein","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hfc.2010.02.001_bib7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2007-12-077388","article-title":"Forging a field: the golden age of iron biology","volume":"112","author":"Andrews","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hfc.2010.02.001_bib8","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1126\/science.1104742","article-title":"Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.hfc.2010.02.001_bib9","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2215\/CJN.05931108","article-title":"Hepcidin\u2013a potential novel biomarker for iron status in chronic kidney disease","volume":"4","author":"Zaritsky","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.hfc.2010.02.001_bib10","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng1777","article-title":"Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression","volume":"38","author":"Babitt","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.hfc.2010.02.001_bib11","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1172\/JCI25683","article-title":"Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload","volume":"115","author":"Niederkofler","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.hfc.2010.02.001_bib12","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1073\/pnas.80.9.2651","article-title":"Transferrin as a fetal growth factor: acquisition of responsiveness related to embryonic induction","volume":"80","author":"Ekblom","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.hfc.2010.02.001_bib13","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1182\/blood-2005-04-1365","article-title":"Altered body iron distribution and microcytosis in mice deficient in iron regulatory protein 2 (IRP2)","volume":"106","author":"Galy","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hfc.2010.02.001_bib14","doi-asserted-by":"crossref","first-page":"30120","DOI":"10.1074\/jbc.M500971200","article-title":"Loss of the von Hippel Lindau tumor suppressor disrupts iron homeostasis in renal carcinoma cells","volume":"280","author":"Alberghini","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.hfc.2010.02.001_bib15","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2004-12-4855","article-title":"Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function","volume":"106","author":"Detivaud","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hfc.2010.02.001_bib16","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2215\/CJN.01370209","article-title":"HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients","volume":"4","author":"Valenti","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.hfc.2010.02.001_bib17","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1681\/ASN.2006070802","article-title":"Molecular control of iron transport","volume":"18","author":"Ganz","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.hfc.2010.02.001_bib18","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.3324\/haematol.2009.010322","article-title":"Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization","volume":"94","author":"Kroot","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.hfc.2010.02.001_bib19","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/j.ajkd.2007.06.008","article-title":"KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target","volume":"50","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.hfc.2010.02.001_bib20","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1681\/ASN.V7122654","article-title":"The evaluation of iron status in hemodialysis patients","volume":"7","author":"Fishbane","year":"1996","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.hfc.2010.02.001_bib21","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1681\/ASN.2006091034","article-title":"Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study","volume":"18","author":"Coyne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.hfc.2010.02.001_bib22","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/sj.ki.5002223","article-title":"Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation","volume":"71","author":"Singh","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.hfc.2010.02.001_bib23","first-page":"58","article-title":"Using iron agents, in\u00a0KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease","volume":"47","author":"National Kidney Foundation","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.hfc.2010.02.001_bib24","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1093\/ndt\/gfh820","article-title":"Hypersensitivity reactions and deaths associated with intravenous iron preparations","volume":"20","author":"Bailie","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.hfc.2010.02.001_bib25","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/ndt\/gfh185","article-title":"On the relative safety of parenteral iron formulations","volume":"19","author":"Chertow","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.hfc.2010.02.001_bib26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/j.ajkd.2005.04.032","article-title":"Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections","volume":"46","author":"Macdougall","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.hfc.2010.02.001_bib27","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1046\/j.1523-1755.2002.00314.x","article-title":"Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran","volume":"61","author":"Michael","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.hfc.2010.02.001_bib29","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2362.2009.02130.x","article-title":"Physicochemical properties of ferumoxytol, a new intravenous iron preparation","volume":"39","author":"Balakrishnan","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.hfc.2010.02.001_bib30","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1681\/ASN.2007101156","article-title":"Ferumoxytol for treating iron deficiency anemia in CKD","volume":"19","author":"Spinowitz","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.hfc.2010.02.001_bib31","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1053\/j.ajkd.2008.08.001","article-title":"Safety of ferumoxytol in patients with anemia and CKD","volume":"52","author":"Singh","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.hfc.2010.02.001_bib32","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1172\/JCI32701","article-title":"Hepcidin regulation: ironing out the details","volume":"117","author":"De Domenico","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.hfc.2010.02.001_bib33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM198701083160203","article-title":"Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial","volume":"316","author":"Eschbach","year":"1987","journal-title":"N Engl J\u00a0Med"},{"key":"10.1016\/j.hfc.2010.02.001_bib34","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1038\/sj.ki.5001972","article-title":"The economic realities of erythropoiesis-stimulating agent therapy in kidney disease","volume":"70","author":"Wish","year":"2006","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.hfc.2010.02.001_bib35","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1681\/ASN.V1061309","article-title":"Hematocrit levels and hospitalization risks in hemodialysis patients","volume":"10","author":"Xia","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.hfc.2010.02.001_bib36","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1681\/ASN.V103610","article-title":"Hematocrit level and associated mortality in hemodialysis patients","volume":"10","author":"Ma","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.hfc.2010.02.001_bib37","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hfc.2010.02.001_bib38","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hfc.2010.02.001_bib39","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Drueke","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hfc.2010.02.001_bib40","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s00467-009-1123-z","article-title":"Target hemoglobin trials in chronic kidney disease: design and interpretation issues","volume":"24","author":"Foley","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.hfc.2010.02.001_bib41","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0140-6736(07)60194-9","article-title":"Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis","volume":"369","author":"Phrommintikul","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.hfc.2010.02.001_bib42","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoietin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hfc.2010.02.001_bib43","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.2215\/CJN.02380607","article-title":"Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets","volume":"2","author":"Fishbane","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.hfc.2010.02.001_bib44","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ki.2008.295","article-title":"Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes","volume":"74","author":"Szczech","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.hfc.2010.02.001_bib45","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/ki.2008.245","article-title":"Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease","volume":"74","author":"Keithi-Reddy","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.hfc.2010.02.001_bib46","article-title":"Soluble p-selectin, platelet microparticles and cd40 ligand in chronic kidney disease patients on erythropoiesis stimulating agents [SA-PO2805] [abstract]","author":"Keithi-Reddy","year":"2008","journal-title":"Am Soc Nephrology Annual Meeting"},{"key":"10.1016\/j.hfc.2010.02.001_bib47","article-title":"Administration of human recombinant erythropoietin (hrepo) induces systemic oxidative stress [abstract]","author":"Parra","year":"2008","journal-title":"J Am Soc Neph"},{"key":"10.1016\/j.hfc.2010.02.001_bib48","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1525-1594.1993.tb00571.x","article-title":"Adverse events of subcutaneous recombinant human erythropoietin therapy: results of a controlled multicenter European study","volume":"17","author":"Klinkmann","year":"1993","journal-title":"Artif Organs"},{"key":"10.1016\/j.hfc.2010.02.001_bib49","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2215\/CJN.05040908","article-title":"Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA)","volume":"4","author":"Krapf","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.hfc.2010.02.001_bib50","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1161\/HYPERTENSIONAHA.107.090423","article-title":"Prevention of erythropoietin-associated hypertension","volume":"50","author":"Lee","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.hfc.2010.02.001_bib51","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMp078100","article-title":"Erythropoietin, the FDA, and oncology","volume":"356","author":"Steinbrook","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hfc.2010.02.001_bib52","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1056\/NEJMoa041773","article-title":"Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy","volume":"353","author":"Watanabe","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hfc.2010.02.001_bib53","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1056\/NEJMp078101","article-title":"Weighing the hazards of erythropoiesis stimulation in patients with cancer","volume":"356","author":"Khuri","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hfc.2010.02.001_bib54","article-title":"Differential modulation of angiogenesis and pro-inflammatory processes by erythropoiesis-stimulating agents in ischemic retinopathy [abstract]","author":"Stitt","year":"2008","journal-title":"Am Soc Nephrology Annual Meeting"},{"key":"10.1016\/j.hfc.2010.02.001_bib55","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00467-007-0673-1","article-title":"Iron, oxidative stress, and clinical outcomes","volume":"23","author":"Agarwal","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.hfc.2010.02.001_bib56","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/sj.ki.5002422","article-title":"Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease","volume":"72","author":"Agarwal","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.hfc.2010.02.001_bib57","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1523-1755.2004.00716.x","article-title":"Parenteral iron nephrotoxicity: potential mechanisms and consequences","volume":"66","author":"Zager","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.hfc.2010.02.001_bib58","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1681\/ASN.2006050500","article-title":"Oxidants in chronic kidney disease","volume":"18","author":"Shah","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.hfc.2010.02.001_bib59","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ki.2009.415","article-title":"A\u00a0secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment","volume":"77","author":"Szczech","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.hfc.2010.02.001_bib60","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000092852","volume":"26","author":"Hertel","year":"2006","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.hfc.2010.02.001_bib61","author":"Patel"},{"key":"10.1016\/j.hfc.2010.02.001_bib62","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood-2006-04-015818","article-title":"Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers","volume":"108","author":"Stead","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hfc.2010.02.001_bib63","article-title":"Hematide maintains hemoglobin levels in dialysis patients irrespective of gender, age, race, or diabetes as cause of chronic kidney disease [TH-PO726] [abstract]","author":"Zeig","year":"2008","journal-title":"Am Soc Nephrology Annual Meeting"},{"key":"10.1016\/j.hfc.2010.02.001_bib64","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1038\/ki.2008.525","article-title":"Optimizing the management of renal anemia: challenges and new opportunities","volume":"111","author":"Locatelli","year":"2008","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.hfc.2010.02.001_bib65","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.exphem.2007.05.007","article-title":"Hematide is immunologically distinct from erythropoietin and corrects anemia induced by anti-erythropoietin antibodies in a rat pure red cell aplasia model","volume":"35","author":"Woodburn","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.hfc.2010.02.001_bib66","first-page":"1034","article-title":"Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia","volume":"9","author":"Macdougall","year":"2008","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.hfc.2010.02.001_bib67","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1182\/blood-2004-04-1631","article-title":"Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease","volume":"104","author":"Nakano","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hfc.2010.02.001_bib68","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1254\/jphs.08R09FM","article-title":"Drug discovery for overcoming chronic kidney disease (CKD): prolyl-hydroxylase inhibitors to activate hypoxia-inducible factor (HIF) as a novel therapeutic approach in CKD","volume":"109","author":"Tanaka","year":"2009","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.hfc.2010.02.001_bib69","article-title":"Correction of Anemia without Exacerbation of Hypertension in a Rat Model of Chronic Kidney Disease: Comparison of FG-2216 to Recombinant Erythropoietin [SA-PO2422] [abstract]","author":"Guo","year":"2008","journal-title":"Am Soc Nephrology Annual Meeting"},{"key":"10.1016\/j.hfc.2010.02.001_bib71","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1097\/01.ASN.0000145457.73744.24","article-title":"The critical role of SRC homology domain 2-containing tyrosine phosphatase-1 in recombinant human erythropoietin hyporesponsive anemia in chronic hemodialysis patients","volume":"15","author":"Akagi","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.hfc.2010.02.001_bib72","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2004-11-4174","article-title":"Human erythropoietin gene therapy for patients with chronic renal failure","volume":"106","author":"Lippin","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hfc.2010.02.001_bib73","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bbrc.2005.11.034","article-title":"The prolonged half-lives of new erythropoietin derivatives via peptide addition","volume":"339","author":"Lee","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.hfc.2010.02.001_bib74","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijpharm.2005.11.014","article-title":"Pharmacokinetic and pharmacodynamic studies following oral administration of erythropoietin mucoadhesive tablets to beagle dogs","volume":"310","author":"Venkatesan","year":"2006","journal-title":"Int J Pharm"},{"key":"10.1016\/j.hfc.2010.02.001_bib75","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.addr.2006.07.015","article-title":"Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway","volume":"58","author":"Bitonti","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.hfc.2010.02.001_bib76","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1681\/ASN.2009111127","article-title":"Does TREAT give the boot to ESAs in the treatment of CKD anemia?","volume":"21","author":"Singh","year":"2010","journal-title":"J Am Soc Nephrol"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713610000371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713610000371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T17:44:35Z","timestamp":1635529475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713610000371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S1551713610000371"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2010.02.001","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}